BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 22454089)

  • 1. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
    Joura EA; Garland SM; Paavonen J; Ferris DG; Perez G; Ault KA; Huh WK; Sings HL; James MK; Haupt RM;
    BMJ; 2012 Mar; 344():e1401. PubMed ID: 22454089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    ; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
    BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
    Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
    Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
    Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
    J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.
    Giuliano AR; Joura EA; Garland SM; Huh WK; Iversen OE; Kjaer SK; Ferenczy A; Kurman RJ; Ronnett BM; Stoler MH; Bautista OM; Moeller E; Ritter M; Shields C; Luxembourg A
    Gynecol Oncol; 2019 Jul; 154(1):110-117. PubMed ID: 30982556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
    Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
    Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of quadrivalent HPV vaccination on HPV related disease in women treated for cervical or vulvar/vaginal disease.
    Kim JJ
    BMJ; 2012 Mar; 344():e1544. PubMed ID: 22454090
    [No Abstract]   [Full Text] [Related]  

  • 11. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.
    FUTURE II Study Group
    J Infect Dis; 2007 Nov; 196(10):1438-46. PubMed ID: 18008221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
    Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
    N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.
    Villa LL; Costa RL; Petta CA; Andrade RP; Ault KA; Giuliano AR; Wheeler CM; Koutsky LA; Malm C; Lehtinen M; Skjeldestad FE; Olsson SE; Steinwall M; Brown DR; Kurman RJ; Ronnett BM; Stoler MH; Ferenczy A; Harper DM; Tamms GM; Yu J; Lupinacci L; Railkar R; Taddeo FJ; Jansen KU; Esser MT; Sings HL; Saah AJ; Barr E
    Lancet Oncol; 2005 May; 6(5):271-8. PubMed ID: 15863374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
    Joura EA; Leodolter S; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Garland SM; Harper DM; Tang GW; Ferris DG; Steben M; Jones RW; Bryan J; Taddeo FJ; Bautista OM; Esser MT; Sings HL; Nelson M; Boslego JW; Sattler C; Barr E; Paavonen J
    Lancet; 2007 May; 369(9574):1693-702. PubMed ID: 17512854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years.
    Yoshikawa H; Ebihara K; Tanaka Y; Noda K
    Cancer Sci; 2013 Apr; 104(4):465-72. PubMed ID: 23331518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
    FUTURE II Study Group
    N Engl J Med; 2007 May; 356(19):1915-27. PubMed ID: 17494925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.
    Villa LL; Costa RL; Petta CA; Andrade RP; Paavonen J; Iversen OE; Olsson SE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; Krogh Gv; Lehtinen M; Malm C; Tamms GM; Giacoletti K; Lupinacci L; Railkar R; Taddeo FJ; Bryan J; Esser MT; Sings HL; Saah AJ; Barr E
    Br J Cancer; 2006 Dec; 95(11):1459-66. PubMed ID: 17117182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
    Nygård M; Hansen BT; Dillner J; Munk C; Oddsson K; Tryggvadottir L; Hortlund M; Liaw KL; Dasbach EJ; Kjær SK
    PLoS One; 2014; 9(2):e88323. PubMed ID: 24505474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled trial of a human papillomavirus type 16 vaccine.
    Koutsky LA; Ault KA; Wheeler CM; Brown DR; Barr E; Alvarez FB; Chiacchierini LM; Jansen KU;
    N Engl J Med; 2002 Nov; 347(21):1645-51. PubMed ID: 12444178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.
    Castellsagué X; Muñoz N; Pitisuttithum P; Ferris D; Monsonego J; Ault K; Luna J; Myers E; Mallary S; Bautista OM; Bryan J; Vuocolo S; Haupt RM; Saah A
    Br J Cancer; 2011 Jun; 105(1):28-37. PubMed ID: 21629249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.